iScience (Jul 2023)
Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates
- Antoni Prenafeta,
- Gregori Bech-Sàbat,
- Alexandra Moros,
- Antonio Barreiro,
- Alex Fernández,
- Manuel Cañete,
- Mercè Roca,
- Luis González-González,
- Carme Garriga,
- Joachim Confais,
- Marion Toussenot,
- Hugues Contamin,
- Andrés Pizzorno,
- Manuel Rosa-Calatrava,
- Edwards Pradenas,
- Silvia Marfil,
- Julià Blanco,
- Paula Cebollada Rica,
- Marta Sisteré-Oró,
- Andreas Meyerhans,
- Cristina Lorca,
- Joaquim Segalés,
- Teresa Prat,
- Ricard March,
- Laura Ferrer
Affiliations
- Antoni Prenafeta
- HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain; Corresponding author
- Gregori Bech-Sàbat
- HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain; Corresponding author
- Alexandra Moros
- HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain
- Antonio Barreiro
- HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain
- Alex Fernández
- HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain
- Manuel Cañete
- HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain
- Mercè Roca
- HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain
- Luis González-González
- HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain
- Carme Garriga
- HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain
- Joachim Confais
- Cynbiose, 1 avenue Bourgelat, 69280 Marcy-l’étoile, France
- Marion Toussenot
- Cynbiose, 1 avenue Bourgelat, 69280 Marcy-l’étoile, France
- Hugues Contamin
- Cynbiose, 1 avenue Bourgelat, 69280 Marcy-l’étoile, France
- Andrés Pizzorno
- CIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007 Lyon, France
- Manuel Rosa-Calatrava
- CIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007 Lyon, France; VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France
- Edwards Pradenas
- IrsiCaixa. AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Spain
- Silvia Marfil
- IrsiCaixa. AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Spain
- Julià Blanco
- IrsiCaixa. AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Spain; University of Vic-Central University of Catalonia (uVic-UCC), 08500 Vic, Catalonia, Spain
- Paula Cebollada Rica
- Infection Biology Laboratory, Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
- Marta Sisteré-Oró
- Infection Biology Laboratory, Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain
- Andreas Meyerhans
- Infection Biology Laboratory, Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain; ICREA (Catalan Institution for Research and Advanced Studies), Pg. Lluís Companys 23, 08010 Barcelona, Spain
- Cristina Lorca
- Unitat Mixta d'Investigació IRTA-UAB en Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain; IRTA, Programa de Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain
- Joaquim Segalés
- Unitat Mixta d'Investigació IRTA-UAB en Sanitat Animal, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona (UAB), 08193 Bellaterra, Spain; Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain
- Teresa Prat
- HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain
- Ricard March
- HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain
- Laura Ferrer
- HIPRA, Avda. La Selva, 135, 17170 Amer (Girona), Spain
- Journal volume & issue
-
Vol. 26,
no. 7
p. 107224
Abstract
Summary: SARS-CoV-2 emerged in December 2019 and quickly spread worldwide, continuously striking with an unpredictable evolution. Despite the success in vaccine production and mass vaccination programs, the situation is not still completely controlled, and therefore accessible second-generation vaccines are required to mitigate the pandemic. We previously developed an adjuvanted vaccine candidate coded PHH-1V, based on a heterodimer fusion protein comprising the RBD domain of two SARS-CoV-2 variants. Here, we report data on the efficacy, safety, and immunogenicity of PHH-1V in cynomolgus macaques. PHH-1V prime-boost vaccination induces high levels of RBD-specific IgG binding and neutralizing antibodies against several SARS-CoV-2 variants, as well as a balanced Th1/Th2 cellular immune response. Remarkably, PHH-1V vaccination prevents SARS-CoV-2 replication in the lower respiratory tract and significantly reduces viral load in the upper respiratory tract after an experimental infection. These results highlight the potential use of the PHH-1V vaccine in humans, currently undergoing Phase III clinical trials.
